Actavis reverses year-ago loss; Merck finishes Idenix buyout; Akorn to divest TB drug to get VersaPharm;

@FiercePharma: Best-read news yesterday: Express Scripts hits Amgen, Zogenix as it punts another 25 drugs. Article | Follow @FiercePharma

@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in diabetes franchise. Report | Follow @TracyStaton

@EricPFierce: Impax 0-2 in inspection double header. FDA issues another Form 483 at Hayward, after spanking Taiwan plant. More | Follow @EricPFierce

@CarlyHFierce: GSK private eyes' son allowed first visit to parents in China jail as trial nears. Article | Follow @CarlyHFierce

> Actavis ($ACT) reported earnings of $0.28 per diluted share for the Q2 compared a loss of $4.27 a share in the same period a year ago. Release

> Merck ($MRK) has completed its buyout of Idenix Pharmaceuticals ($IDIX). Release

> The National Health System in the U.K. has agreed to pay for a new subcutaneous formulation of Roche's ($RHHBY) cancer drug MabThera (rituximab) for patients with follicular lymphoma. Story

> Lake Forest, IL-based Akorn ($AKRX) reported earnings of $0.07 per diluted share in Q2 down from $0.11 per diluted share in the same period last year. Release

> Akorn ($AKRX) also announced that it has gotten FTC approval to buy specialty prescription drug company VersaPharm if it agrees to sell the rights to its generic tuberculosis drug rifampin. Story

> Novartis ($NVS) has officially put up for sale a plant in Suffern, NY, that it intends to close next year, laying off most of the 525 employees. Story

Medical Device News

@FierceMedDev: Cohera's surgical adhesive narrowly wins FDA panel support. Article | Follow @FierceMedDev

@StacyALawrence: Smith & Nephew touts acquisitions, offers bulk hospital buying. Story | Follow @StacyALawrence

@VarunSaxena2: ICYMI: FDA announces intention to comprehensively regulate lab-developed tests. Article | Follow @VarunSaxena2

@MichaelGFierce: Nature-inspired artificial cilia could help move drugs to a target. Story | Follow @MichaelGFierce

@EmilyWFierce: Small, portable telemedicine device conducts 33 Dx tests and could improve health monitoring in India. More from Quartz India | Follow @EmilyWFierce

> Nanopores, microfluidics get $14.5M from NIH for new DNA sequencing tech. News

> Earbuds: The wearable med device of the future? Apple, Intel think so. More

> Lombard Medical scores Japanese approval for endovascular stent graft system. Story

> Capnia IPO to raise $20M to market neonatal hemolysis test. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Roche's pRED buys out Santaris in $450M RNA acquisition. Article | Follow @FierceBiotech

@JohnCFierce: So, Juno has now raised more than $300M in less than 12 months. Why not go public while they're at it? Release | Follow @JohnCFierce

@DamianFierce: A lot of money: Juno has raised more than $300M in a year to develop a promising new approach to cancer treatment. More | Follow @DamianFierce

> Japanese researcher found dead amid a swirling stem cell research scandal. More

> How big is Novartis's LCZ696 heart drug? Experts bet on a key number. Article

> Mapp Bio stays mum during Ebola media storm. Item

> Insmed shares shrivel as PhIII Arikayce plan chills hopes for quick OK. Story

Biotech Research News

> Experimental vaccine for C. difficile successful in animal models. Report

> Mice without regulator protein show longer life, fewer tumors. More

> Senate bill would set NIH budget floor, raise funding over 7 years. Article

> Scripps researchers uncover new signaling pathway in brown fat cells. Story

> Peptide measurement predicts Ebola deadliness. Item

Pharma Manufacturing News

> Tough FDA oversight pushing some API makers to look for U.S. expansion. Item

> Novartis' U.S. Diovan plant gets 'For Sale' sign. Article

> FDA piles misery onto Impax with 2nd Form 483 in a week. News

> Labor disputes lead Pfizer to lock workers out of plant in India. Story

> Glenmark to invest $17 million in production facilities in North Carolina. Article

And Finally... After more than 80 years, Bayer has decided to give up the neon sign atop Mt. Washington in Pittsburgh, which owner Lamar Advertising says will go to a new, yet unnamed client. Story

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.